Results 181 to 190 of about 6,939,801 (335)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

VO2 Responses to Running Speeds Above Intermittent Critical Speed

open access: gold, 2012
Rafael Alves de Aguiar   +3 more
openalex   +2 more sources

Author response: Centrally expressed Cav3.2 T-type calcium channel is critical for the initiation and maintenance of neuropathic pain

open access: gold, 2022
Sophie L. Fayad   +13 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

open access: yesMolecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto   +13 more
wiley   +1 more source

Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer. [PDF]

open access: yesNPJ Syst Biol Appl, 2018
Ebhardt HA   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy